The Medicines Co. says sees Q1 net revenue $145M-$155M, consensus $157.55M Says sees GAAP EPS loss (33c)-(24c) for Q1, may not compare to consensus of 27c. Says Q1 will be "burdened" by a number of one-time business circumstances. Sees FY13 worldwide net revenue growth 20%-22%, consensus $655.13M. Comments made on the Q4 earnings conference call.
The FDA Cardiovascular & Renal Drugs Advisory Committee to hold a meeting The Committee discusses The Medicines Company's New Drug Application (NDA) 204958 Cangrelor injection for proposed indication of reduction of thrombotic cardiovascular events at a meeting being held at FDA Silver Spring, Maryland offices on April 15 at 8 am. Webcast Link